MSI-H/MMRd y MSS/ pMMR
Quiénes somos
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
Estudio de fase 2 de CA102N combinado con TAS-102 comparado con bevacizumab combinado con TAS-102 en sujetos con cáncer colorrectal metastásico recidivante y/o refractario.
Estudio de CNA3103 (células CAR-T autólogas dirigidas a LGR5) administrado a sujetos con cáncer colorrectal metastásico.
RC48-ADC combinado con bevacizumab en cáncer colorrectal avanzado HER2-positivo
Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
Células T transgénicas CD8+ y CD4+ autólogas que expresan receptores de células T específicos de la mutación KRASG12V de alta afinidad (FH-A11KRASG12V-TCR) para el tratamiento de pacientes con cánceres metastásicos de páncreas, colorrectal y de pulmón de células no pequeñas con mutaciones KRAS G12V.
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
